All In Biotech

Drug Trial Radar · NCT03101930

Cardiovascular Effects of GLP-1 Receptor Activation

Last checked: Nov 19, 2026Latest source record: Oct 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 329 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

329

Actual

Start

May 1, 2017

Primary completion

Jun 24, 2021

Study completion Jun 24, 2021

Sponsor

Lead sponsor
Vanderbilt University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Heart Association
First posted
Apr 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that exceed the benefits of weight loss, and that genetic or other individual factors that modulate GLP1R sensitivity can modify the effect of these analogues on cardiovascular risk.

Conditions

  • Obesity
  • PreDiabetes

Interventions

  • LiraglutideDrug

    subcutaneous liraglutide daily

  • SitagliptinDrug

    oral sitagliptin daily

  • hypocaloric dietOther

    Reduced calorie intake to achieve weight loss.

  • PlacebosDrug

    Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.

  • Exendin (9-39)Drug

    All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Flow-mediated DilationTime frame: Baseline to 2 and 14 weeks
  2. Urine Albumin-to-creatinine RatioTime frame: Baseline to 13 weeks
  3. Change in Plasminogen Activator Inhibitor-1Time frame: Baseline to 2 and 14 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University Medical Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.